Current Dong-A management likely to win

Published: 2007-10-29 07:00:00

Updated: 2007-10-29 07:00:00

Pharmaceutical sources says the current management led by its incumbent Chairman Kang Shin-ho will get more advantageous position as Mirae Asset Investments, the largest shareholder of Dong-A Pharmaceutical, announced on October 23 that it sided with current Dong-A management.

The leading asse...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK